CORT at a glance
Corcept Therapeutics Inc (CORT, SEC CIK 1088856) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Corcept Therapeutics Inc (CORT) reported revenue of $761.4 million (up 12.8% from FY2024) and net income of $99.7 million. Diluted EPS was $0.82.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Corcept Therapeutics Inc (CORT) shares worth $4.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by WILSON JAMES N on November 13, 2026 of 2,191 shares at $71.80 per share.
- In the last 90 days, CORT insiders reported 0 open-market purchases ($0) and 41 open-market sales ($28.5M) on Form 4, a net sale of $28.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $761.4M
- +12.8% vs prior year
- Insiders · 90 days
- 0 buys · 41 sells
- Net −$28.5M
- 13F holders
- 35 funds
- $4.6B · +0 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New FDA relacorilant review risk: December 30, 2025 CRL triggered additional analyses and NDA resubmission
- New regulatory risk: HHS re-examination of mifepristone safety announced September 2025
- Competitive risk: Teva’s generic mifepristone materially reduced Hypercortisolism Product pricing
- Operational concentration: Curant collects payments from insurers representing more than 99% of hypercortisolism revenue
- Financial risk: OBBBA Medicaid funding cuts may increase patient-assistance costs and reduce product access
Management Discussion & Analysis
- Revenue $340.5M, up 64.0% YoY from $207.6M, driven by Hypercortisolism Products and Lifyorli
- Hypercortisolism Products revenue $249.1M, up from $207.6M; Lifyorli generated $91.4M after April launch
- Cost-of-sales margin 98.6% vs 97.8% YoY, with cost of sales 1.4% vs 2.2% of revenue
- Cash, equivalents and marketable securities $662.3M vs $532.4M; operating cash flow $159.7M vs $103.5M
- 2026 outlook: R&D expense approximately unchanged; SG&A higher, IRA may reduce profits in 2026 and beyond
AI summary of the CORT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings figures and business developments for investor review
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Corporate update accompanying quarterly results
Item EX-99.1: Item EX-99.1
- Q3 revenue $340.5M, up 64% year over year, led by Lifyorli revenue $91.4M and Korlym revenue $249.1M
- Net income $126.8M, up from $19.7M, with diluted EPS $1.01 versus $0.16
Item 7.01: Regulation FD Disclosure
- CEO transition announced: Justin Gunn succeeds retiring Mr. Maduck
- Leadership change creates execution and strategy continuity considerations
Item 5.02: Departure/Appointment of Directors or Principal Officers
- President of Corcept Endocrinology Sean Maduck resigns effective October 1, 2026
- No disagreement cited with operations, financial statements, policies or practices
Item EX-99.1: Item EX-99.1
- Sean Maduck retiring as Endocrinology president after 14 years, remaining as senior commercial advisor
- Justin Gunn assumes Endocrinology leadership October 1 and joins Executive Team, reporting to CEO Joseph Belanoff
Item 2.02: Results of Operations and Financial Condition
- Corcept announced financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed results and corporate update
Item 7.01: Regulation FD Disclosure
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed earnings figures and operational developments
Item EX-99.1: Item EX-99.1
- Q2 revenue $256.1M, up 32% YoY, driven by $47.6M Lifyorli launch revenue alongside $208.6M Korlym revenue
- 2026 revenue guidance raised to $1.1B-$1.2B, signaling confidence in accelerating oncology demand and Cushing’s syndrome prescriptions
AI summaries of CORT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CORT
Don't miss the next CORT filing
- Alerts as it files. A push when CORT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CORT, by share count.
- Ask anything. An AI agent that reads every CORT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| WILSON JAMES N | Sell | Nov 13, 2026 | 2,191 | $71.80 |
| WILSON JAMES N | Sell | Nov 13, 2026 | 7,221 | $72.87 |
| WILSON JAMES N | Sell | Nov 13, 2026 | 25 | $74.28 |
| WILSON JAMES N | Sell | Nov 13, 2026 | 563 | $73.42 |
| Swisher Daniel N JR | Sell | Nov 10, 2026 | 1,500 | $74.07 |
| Swisher Daniel N JR | M | Nov 10, 2026 | 1,100 | - |
| Swisher Daniel N JR | M | Nov 10, 2026 | 400 | - |
| Swisher Daniel N JR | M | Nov 10, 2026 | 1,100 | $14.08 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $675.0M | $761.4M |
| Operating Income | - | $137.0M | $44.8M |
| Net Income | $106.1M | $141.2M | $99.7M |
| Op. Margin | - | 20.3% | 5.9% |
| Net Margin | - | 20.9% | 13.1% |
| Balance Sheet | |||
| Total Assets | $621.5M | $840.6M | $836.7M |
| Equity | - | $679.6M | $647.8M |
| ROE | - | 20.8% | 15.4% |
| Per Share | |||
| EPS | $0.94 | $1.23 | $0.82 |
| Cash Flow | |||
| Operating CF | - | $198.1M | $142.0M |
| CapEx | $139K | $2.2M | $211K |
Source: XBRL data in Corcept Therapeutics Inc (CORT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CORT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $4.63B |
| Q2 2026 | 35 | $3.90B |
| Q1 2026 | 34 | $1.76B |
| Q4 2025 | 33 | $1.51B |
| Q3 2025 | 34 | $3.75B |
| Q2 2025 | 33 | $3.20B |
| Q1 2025 | 31 | $3.64B |
| Q4 2024 | 25 | $1.49B |
- AQR Capital Management+1.06M (+41%)
- D.E. Shaw & Co+1.04M (+118%)
- Two Sigma Investments+295.6K (+48%)
- Bridgewater Associates LP+210.6K (+366%)
- Vanguard Capital Management LLC+180.9K (+4%)
- BlackRock−2.24M (-18%)
- Renaissance Technologies LLC−411.5K (-8%)
- Dimensional Fund Advisors−354.4K (-27%)
- Vanguard Portfolio Management LLC−267.6K (-5%)
- Goldman Sachs Group−254.1K (-45%)
- FMR LLC (Fidelity)−3.34M
Source: 13F-HR filings on SEC EDGAR (aggregated from 260 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CORT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CORT SEC filings: frequently asked questions
Are CORT insiders buying or selling?
In the last 90 days, Corcept Therapeutics Inc (CORT) officers, directors and 10% owners reported no open-market purchases and 41 open-market sales worth $28.5 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CORT stock?
As of September 30, 2026, the largest Corcept Therapeutics Inc (CORT) holders among the 13F filers tracked by SignalX were BlackRock ($1.2 billion), Renaissance Technologies LLC ($558.9 million), Vanguard Portfolio Management LLC ($550.5 million), Vanguard Capital Management LLC ($501.6 million), AQR Capital Management ($419.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CORT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Corcept Therapeutics Inc (CORT) reported revenue of $761.4 million (up 12.8% from FY2024) and net income of $99.7 million. Diluted EPS was $0.82. The figures come from the XBRL data in the 10-K.
What did CORT report in its latest 8-K?
Corcept Therapeutics Inc (CORT) filed an 8-K on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.
What are the latest CORT SEC filings?
Corcept Therapeutics Inc (CORT) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 17, 2026.
What is CORT's SEC CIK number?
Corcept Therapeutics Inc (CORT)'s SEC Central Index Key (CIK) is 1088856. EDGAR lists every CORT filing under that number.
Ask anything about CORT
The research agent reads CORT's filings, financials, insider trades and 13F holders, then answers with sources.